Consequently, the goal of our research is to extend the flow cytometry examination of platelet activation (CD63, CD62p,) adhesion (CD42a, CD42b) and aggregation (CD41, CD61) markers to the particular clinical context of the patient with AML. The gene discussed is SELP; the disease is acute myeloid leukemia.